Device Trial Radar · NCT04105699
Evaluation of Immunoassay Measurements of Pancreatic Stone Protein Performed on abioSCOPE® Device With the PSP Assay on ICU Patients at Risk of Sepsis as an Aid in Identifying Sepsis
Last checked: Nov 19, 2026Latest source record: Jan 30, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
544
Actual
Start
Dec 10, 2019
Primary completion
Aug 23, 2023
Study completion Dec 28, 2023
Sponsor
- Lead sponsor
- Abionic SANot on our public-company list
- Sponsor type
- Industry
- Collaborators
- Avania
- First posted
- Sep 26, 2019
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, prospective, biomarker-result-blinded observational study evaluating immunoassay measurements of pancreatic stone protein (PSP) performed on Abionic's abioSCOPE device with the PSP assay on ICU patients at risk of sepsis as an aid in identifying sepsis.
Conditions
- Sepsis
Interventions
Blood samplingDevice
Daily blood sample which will be taken for the PSP measurement using the abioSCOPE as well as another daily sample taken for central analysis of biomarkers of inflammation, infection and/or sepsis (including but not limited to C-reactive protein \[CRP\] and Procalcitonin \[PCT\]).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Ability of the abioSCOPE PSP assay performed on day 1 of a participant's ICU admission to correctly identify those with sepsis.Time frame: Day 1
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Northwestern University
Chicago, Illinois
Rush University Medical Center
Chicago, Illinois
University of Kentucky
Lexington, Kentucky
2 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.